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Abstract
Background
Assessing the relationship between lung cancer and metabolic conditions is challenging
because of the confounding effect of tobacco. Mendelian randomization (MR), or the use of
genetic instrumental variables to assess causality, may help to identify the metabolic drivers
of lung cancer.
Methods and findings
We identified genetic instruments for potential metabolic risk factors and evaluated these in
relation to risk using 29,266 lung cancer cases (including 11,273 adenocarcinomas, 7,426
squamous cell and 2,664 small cell cases) and 56,450 controls. The MR risk analysis sug-
gested a causal effect of body mass index (BMI) on lung cancer risk for two of the three
major histological subtypes, with evidence of a risk increase for squamous cell carcinoma
(odds ratio (OR) [95% confidence interval (CI)] = 1.20 [1.01–1.43] and for small cell lung
cancer (OR [95%CI] = 1.52 [1.15–2.00]) for each standard deviation (SD) increase in BMI
[4.6 kg/m2]), but not for adenocarcinoma (OR [95%CI] = 0.93 [0.79–1.08]) (Pheterogeneity =
4.3x10-3). Additional analysis using a genetic instrument for BMI showed that each SD
increase in BMI increased cigarette consumption by 1.27 cigarettes per day (P = 2.1x10-3),
providing novel evidence that a genetic susceptibility to obesity influences smoking patterns.
There was also evidence that low-density lipoprotein cholesterol was inversely associated
with lung cancer overall risk (OR [95%CI] = 0.90 [0.84–0.97] per SD of 38 mg/dl), while fast-
ing insulin was positively associated (OR [95%CI] = 1.63 [1.25–2.13] per SD of 44.4 pmol/l).
Sensitivity analyses including a weighted-median approach and MR-Egger test did not
detect other pleiotropic effects biasing the main results.
Causality appraisal of metabolic factors on risk of lung cancer subtypes
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Conclusions
Our results are consistent with a causal role of fasting insulin and low-density lipoprotein
cholesterol in lung cancer etiology, as well as for BMI in squamous cell and small cell carci-
noma. The latter relation may be mediated by a previously unrecognized effect of obesity on
smoking behavior.
Introduction
Lung cancer is the leading cause of cancer mortality [1]. Most lung cancers are caused by
tobacco smoking [2], although associations have also been reported with a range of inflamma-
tory and metabolic conditions. Observational studies have indicated an inverse relationship
for both body mass index (BMI) [3–7] and lipid levels [8,9], as well as a positive correlation
with dietary glycemic index [10] and insulin levels [11], with lung cancer risk. However, given
the strong effect of tobacco smoking on lung cancer risk, and the well described association
between tobacco consumption and alterations in body weight [12–14], traditional observa-
tional studies are unlikely to fully account for the confounding effect of tobacco exposure
when describing the relationship between lung cancer and obesity or metabolic conditions.
Mendelian randomization (MR) is an analytical approach based on genetic markers of an
exposure (i.e. an instrumental variable) that is less sensitive to reverse causation and confound-
ing than traditional regression analyses in observational studies [15]. Inherited gene variants
associated with the risk factors of interest should act as unconfounded markers of those risk
factors, assuming an absence of pleiotropy [16]. In this instance, an association between the
genetic variant and the outcome implies that the risk factor of interest may have a causal effect
on the outcome [17]. Previous MR analyses on lung cancer risk showed that a genetic score for
increased BMI raised the risk for lung cancer, especially for squamous cell carcinoma and
small cell lung cancer [18,19]. These results are in contradiction to observational findings, con-
firming the utility of MR analyses for this exposure.
The goal of the current study was to use genetic variations associated with a range of meta-
bolic factors, including obesity, body shape, dyslipidemia and hyperglycemia, to further inves-
tigate the causal relationship between these metabolic exposures and lung cancer. The method
applied in this study is called two-sample MR, which combines summary statistics on genetic
variant-exposure and genetic variant-outcome associations from different samples [20,21].
Furthermore, we sought to confirm that the genetic control of these metabolic phenotypes did
not influence cigarette smoking behavior.
Methods
Genetic instruments for obesity and metabolic parameters
Genetic instruments for potential risk factors were independent (linkage disequilibrium (LD)
R2 < 0.01 in European 1000 Genomes Phase3 samples [22]) single nucleotide polymorphisms
(SNPs) that were associated with the trait of interest in the most recent genome-wide associa-
tion study (GWAS) (P<5x10-8) on European ancestry samples. Results from the Genetic
Investigation of ANthropometric Traits (GIANT) consortium were used to identify genetic
proxies for body mass index (BMI) [23], and waist to hip ratio [24]. High-density and low-den-
sity lipoprotein cholesterol (HDL and LDL), total cholesterol and triglycerides were selected as
lipid profile components. Genetic loci influencing bloodstream levels of these lipids were
Causality appraisal of metabolic factors on risk of lung cancer subtypes
PLOS ONE | https://doi.org/10.1371/journal.pone.0177875 June 8, 2017 3 / 16
identified from GWA data provided by the Global Lipids Genetic Consortium (GLGC) [25].
Additionally, genetic instruments of low frequency were also identified for HDL, LDL choles-
terol and triglycerides [26]. Finally, hyperglycemia and hyperinsulinemia parameters were
reported within the Meta-Analysis of Glucose and Insulin related traits Consortium (MAGIC)
at fasting levels and during an oral glucose tolerance test (OGTT). Genetic instruments were
identified for plasma levels of fasting glucose, fasting insulin and 2-hour post-challenge glucose
[27]. For these metabolic parameters, in order to reduce potential pleiotropic effect from BMI,
SNPs that were not associated with the phenotype once adjusted for BMI (P>0.05) were
excluded from our analyses. For each identified SNP, the reported effect was for the increasing
trait allele expressed in standard deviations (SD) of the trait per-allele (βGP) along with the
standard error (SEGP). For the studies in which the genetic effects were not originally reported
in SDs of the trait, they were recalibrated according to the mean SD, weighted for sample size,
reported across different case-control samples. SNPs with ambiguous strand codification (A/T
or C/G) were replaced by SNPs in tight genetic linkage (R2>0.8) using the proxysnps R package
(European populations) (R Project) or removed from the analyses. Details on i) the number of
SNPs identified for each potential risk trait, ii) the mean and SD of the traits in the discovery
GWAS, and iii) the proportion of trait variance explained by the genetic proxies are presented
in Table 1.
Lung cancer association results
GWAS results on overall lung cancer risk and by histology type were obtained from the
recently completed meta-analyses [28] comprising the previous TRICL-ILCCO lung cancer
GWAS (11,177 lung cancer cases and 40,396 controls) [29] and an additional 18,089 lung can-
cer samples and 16,054 controls genotyped using the Illumina Infinium OncoArray-500K
BeadChip (Illumina Inc. San Diego, CA). The overall sample size was 29,266 lung cancer cases
and 56,450 controls. GWAS analyses were stratified by histology, including 11,273 adenocarci-
nomas, 7,426 squamous cell carcinomas and 2,664 small cell lung cancers. Additionally, analy-
ses were performed stratified by smoking status defined as ever smokers (current and former
smokers; 23,223 cases and 16,964 controls) and never smokers (2,355 cases and 7,504 con-
trols). SNPs with imputation quality score (R2) less than 0.7 were removed from the datasets.
For all SNPs used as instruments in this report, SNP to phenotype effect (βGP) and SNP to dis-
ease effect (βGD) for each lung cancer subgroup can be observed in S1 Table.
Table 1. Number of identified instrumental SNPs for metabolic factors, phenotype distribution in the discovery sample, and proportion of pheno-
type variance explained by the instruments. SD: standard deviation.
Phenotype N SNP Mean ± SD Units Variance explained (%) Consortium Publication for instruments
Body mass index 73 27.0 ± 4.6 kg/m2 2.7 GIANT Locke et al 2015 [23]
Waist to hip ratio 32 1.1 ± 0.1 cm/cm 1.4 GIANT Shungin et al 2015 [24]
High density cholesterol 63 53.3 ± 15.5 mg/dl 13.7 GLGC Willer et al 2013 [25]
Low density cholesterol 50 133.6 ± 38.0 mg/dl 14.6 GLGC Willer et al 2013 [25]
Total cholesterol 67 213.28 ± 42.6 mg/dl 15.0 GLGC Willer et al 2013 [25]
Triglycerides 39 140.85 ± 87.8 mg/dl 11.7 GLGC Willer et al 2013 [25]
HDL rare variants 11 1.4 ± 0.4 mmol/l 4.1 - Helgadottir et al 2016 [26]
Non-HDL rare variants 11 4.0 ± 1.2 mmol/l 4.1 - Helgadottir et al 2016 [26]
Triglycerides rare variants 7 1.3 ± (0.8–2.2) mmol/l 2.4 - Helgadottir et al 2016 [26]
Fasting glucose 25 5.2 ± 0.8 mmol/l 4.8 MAGIC Scott et al 2012 [27]
Fasting insulin 11 56.9 ± 44.4 pmol/l 1.2 MAGIC Scott et al 2012 [27]
2h post-challenge glucose 6 5.6 ± 1.7 mmol/l 1.7 MAGIC Scott et al 2012 [27]
https://doi.org/10.1371/journal.pone.0177875.t001
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Power assessment
Power calculations on MR analyses were performed according to Burgess [30], given the num-
ber of cases and controls of the lung cancer subgroups, for five genetic instruments accounting
for different proportion of explained variance (1%, 2.5%, 5%, 10% and 15%) within the range
of our genetic instrument sets (see Table 1). Power calculations are presented in S1 Fig.
Mendelian randomization analyses on lung cancer
The causal risk effects of metabolic factors on lung cancer overall, as well as by histology and
other subgroups were estimated using a likelihood-based approach, which is considered the
most accurate method to estimate causal effects when there is a continuous log-linear associa-
tion between risk factor and disease risk [20]. The resulting odds ratio (OR) and 95% confi-
dence interval (CI) provide an estimate of relative risk caused by each SD increase in the
exposure. We investigated the heterogeneity of causal effects by histology and by smoking sta-
tus, estimating the I2 statistic assuming a fixed-effect model using the meta R package (R proj-
ect). We also provide OR estimates using the complementary weighted median method
wherein the causal effect estimate is weighted towards the median of the distribution of instru-
mental SNPs [31]. This approach is less sensitive to individual instrumental SNPs behaving as
outliers. Furthermore, because OR estimates can be confounded if the instrumental genetic
variants are also associated with other causal risk factors, i.e. through directional pleiotropy,
we also performed MR-Egger [32]. This approach involves a weighted linear regression of the
SNP to disease effects (βGD) on the SNP to phenotype effects (βGP), and provides a direct esti-
mate of any directional pleiotropy under the assumption that pleiotropic biases affecting the
overall MR risk estimates are acting in the same direction [33]. Additionally, MR-Egger regres-
sion is able to identify SNPs behaving as genetic outliers, providing Bonferroni corrected P-
values. We also provide a funnel plot of the fold risk increase (exp(βGD/βGP)) vs. the instru-
mental strength of each SNP (βGP/SEGD
2) to allow visual assessment of asymmetry of instru-
mental causal estimates. These plots were generated using the ggplot2R package (R Project).
Assessment of association between the genetic instruments and other
phenotypes
To evaluate whether MR lung cancer risk estimates could be generated by other phenotypes
than the instrumented ones, the association of genetic instruments with other phenotypes was
assessed. The effects of our genetic instruments on cigarette smoking was evaluated using a
novel online platform for Mendelian randomization based on summary genetic association
data from GWAS (MR-Base; http://www.mrbase.org/) [34]. Genetic effects on cigarette smok-
ing (cigarettes per day) were obtained from the Tobacco and Genetics (TAG) consortium [35].
TAG data were generated from 16 independent studies which included 38,181 smokers with
information on number of smoked cigarettes per day. We also assessed the association of dysli-
pidemia and hyperglycemia genetic instruments with BMI using data from the GIANT con-
sortium [23].
Results
Obesity and body shape parameters
Based on 72 SNPs used as genetic instruments for BMI, we estimated an overall OR (per SD
increase in BMI (4.6 kg/m2)) of 1.07 (95%CI = 0.96–1.20) for lung cancer risk (Fig 1). How-
ever, stratified analyses by histology subtypes revealed heterogeneity in the causal effect esti-
mates (Pheterogeneity = 4.3x10-3), with no effect on adenocarcinoma (OR [95%CI] = 0.93 [0.79–
Causality appraisal of metabolic factors on risk of lung cancer subtypes
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1.08]), but an increased risk for squamous cell carcinoma (OR [95%CI] = 1.20 [1.01–1.43])
and small cell lung cancer (OR [95%CI] = 1.52 [1.15–2.00]) (Fig 2). Analyses stratified by
smoking status showed a null effect of BMI in never smokers (OR [95%CI] = 0.83 [0.60–1.16])
and in ever smokers (OR [95%CI] = 1.12 [0.97–1.29]) (Pheterogeneity = 0.10) (Fig 2). Weighted
median MR approach provided similar risk estimates for the different lung cancer types (S2
Table). The MR-Egger intercept test revealed the presence of bias on the initial risk estimation
on lung cancer overall and in ever-smokers (S3 Table), with MR-Egger risk estimates indicat-
ing no effect of BMI on lung cancer overall. Potential asymmetry of the SNP’ risk estimates
reflected the presence of directional pleiotropy for lung cancer overall (Fig 3A). Funnel plots
for the other histological types can be observed in the funnel plots included in Fig 3B–3F.
Regarding waist-to-hip ratio, there was no evidence of causal effect on lung cancer overall (OR
[95%CI] = 1.04 [0.87–1.25]) (Fig 1) or histology subgroups (S2 Fig). Sensitivity analyses did
not detect any effect biasing the initial risk estimates (S2 and S3 Tables). Funnel plots can be
observed in S3 Fig.
Blood lipid levels
There was no consistent evidence of a causal effect of HDL on lung cancer overall (OR
[95%CI] = 1.01 [0.94–1.07] for instrumental common SNPs, and OR [95%CI] = 1.07 [0.95–
1.21] for instrumental rare SNPs) (Fig 1), nor any lung cancer subgroup (S4–S7 Figs).
Fig 1. Forest plot of lung cancer overall risk for one standard deviation (Table 1) increase in each phenotype provided by the MR likelihood-
based approach. CI: Confidence interval. P: P value.
https://doi.org/10.1371/journal.pone.0177875.g001
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Triglyceride levels did not indicate any effect on lung cancer overall; (OR [95%CI] = 0.98
[0.91–1.06] for instrumental common SNPs and OR [95%CI] = 0.87 [0.70–1.08] for instrumen-
tal rare SNPs) (Fig 1), or for lung cancer subtypes (S8–S11 Figs). An inverse relationship was
observed with overall lung cancer risk for each SD increase in LDL (approximately 38.0 mg/dl)
(OR [95%CI] = 0.90 [0.84–0.97] for instrumental common SNPs (Fig 1), although stratified
analyses did not provided a consistent inverse association among histology types (OR of 0.93
for adenocarcinoma (95%CI = 0.85–1.03), 0.88 for squamous cell carcinoma (95%CI = 0.79–
0.98), and 0.96 for small cell lung cancer (95%CI = 0.81–1.14) (Fig 4 and S12 Fig for funnel
plots). Additionally, LDL instrumental rare SNPs did not provide evidence of association with
lung cancer overall (OR [95%CI] = 1.09 [0.93–1.27]) (Fig 1) or subtypes (S13 and S14 Figs for
funnel plots). Finally, total cholesterol showed a similar pattern of association with lung cancer
overall and with subtypes that LDL common SNPs (OR of 0.94 for lung cancer overall (95%
CI = 0.88–1.01), OR of 1.01 for adenocarcinoma (95%CI = 0.92–1.10), 0.89 for squamous cell
carcinoma (95%CI = 0.80–1.00), and 0.93 for small cell lung cancer (95%CI = 0.79–1.10)) (S15
and S16 Figs for funnel plots).
Insulin resistance parameters
Among glucose and insulin parameters, fasting insulin was associated with an increased risk in
overall lung cancer (OR [95%CI] = 1.63 [1.25–2.13] per each SD increase [44.4 pmol/l]) (Fig
1). Stratified analyses provided consistent associations with all histology subtypes (Fig 5), with
a risk increase of 1.60 for adenocarcinoma (95%CI = 1.12–2.31), 1.84 for squamous cell carci-
noma (95%CI = 1.20–2.81), and 2.46 for small cell lung cancer (95%CI = 1.26–4.81). Stratified
analyses by smoking status showed some heterogeneity in causal effects (Pheterogeneity = 0.16)
(Fig 5), with a clear increased risk among ever smokers (OR [95%CI] = 1.86 [1.33–2.60]), but
no association among never smokers (OR [95%CI] = 1.01 [0.46–2.20]). Sensitivity tests identi-
fied rs4865796 as an outlier SNP in the analyses for lung adenocarcinoma subtype and lung
cancer overall in ever smokers. Removing this SNP, the analyses indicated slightly higher levels
of risk associated with this genetic instrument (Funnel plots in S17 Fig).
Fig 2. Forest plot of lung cancer risk for each SD increase in BMI (approximately 4.6 kg/m2) observed in the likelihood-based MR approach.
95%CI: 95% Confidence Interval; P: P value. I2: between-strata heterogeneity. PHet: P value of between-strata heterogeneity.
https://doi.org/10.1371/journal.pone.0177875.g002
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Fig 3. Funnel plots for the distribution of risk estimates of BMI instrumental SNPs along with MR causal effect lung cancer subtypes. OR:
Odds ratio; Int: Intercept; P: P value.
https://doi.org/10.1371/journal.pone.0177875.g003
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Fasting glucose showed little evidence for an association with overall lung cancer risk (OR
per SD of 0.8 mmol/l = 1.10; 95%CI = 0.96–1.26) (Fig 1), nor for adenocarcinoma (OR [95%
CI] = 1.03 [0.85–1.24] or small cell lung cancer (OR [95%CI] = 1.19 [0.83–1.68]), where a posi-
tive association with risk was seen for squamous cell carcinoma (OR [95%CI] = 1.32 [1.06–
1.65]) (S18 and S19 Figs for funnel plots). Finally, 2-hour post-challenge glucose showed no
evidence of causality for lung cancer overall (OR [95%CI] = 0.96 [0.77–1.20]) (Fig 1) or any
lung cancer subgroup (S20 and S21 Figs for funnel plots).
Fig 4. Forest plot of lung cancer risk for each SD increase in LDL (approximately 38.0 mg/dl) observed in the likelihood-based MR approach
using the instrument set of common SNPs. 95%CI: 95% Confidence Interval; P: P value. I2: between-strata heterogeneity. PHet: P value of
between-strata heterogeneity.
https://doi.org/10.1371/journal.pone.0177875.g004
Fig 5. Forest plot of lung cancer risk for each SD increase in fasting insulin (approximately 44.4 pmol/L) observed in the likelihood-based
MR approach. 95%CI: 95% Confidence Interval; P: P value. I2: between-strata heterogeneity. PHet: P value of between-strata heterogeneity.
https://doi.org/10.1371/journal.pone.0177875.g005
Causality appraisal of metabolic factors on risk of lung cancer subtypes
PLOS ONE | https://doi.org/10.1371/journal.pone.0177875 June 8, 2017 9 / 16
Assessment of association between the genetic instruments and other
phenotypes
Using MR-Base, we also evaluated the association between cigarette smoking for each genetic
instrument associated with lung cancer risk, including BMI, LDL, and fasting insulin. Each SD
increase in BMI increased cigarette consumption by 1.27 cigarettes (95%CI = 0.46:2.07;
P = 2.1x10-3; MR likelihood-based approach), while the other metabolic genetic instruments
were not associated with cigarette smoking (MR likelihood-based estimate per SD increase
[95%CI] = -0.35 [-0.92:0.22] for LDL and 1.21 [-0.67:3.08] for fasting insulin). Additionally,
each SD increase in LDL was inversely associated with BMI (-0.02 SD in BMI (95%CI = -0.04:-
3.8x10-3; P = 0.02), while each SD increase in fasting was not associated with BMI (0.07 SD in
BMI (95%CI = -0.01:0.15; P = 0.10)).
Discussion
We have used existing data from large GWAS on metabolic factors to identify potentially
causal risk factors of lung cancer that are amenable to intervention. Our results suggested that
higher BMI is associated with an increase in risk of squamous and small cell carcinoma of the
lung, and that this relation may be mediated by altered smoking behavior. Additionally, we
found consistent evidence of a positive association between fasting insulin and overall lung
cancer risk, as well as an inverse relationship between LDL levels and lung cancer risk.
Obesity and related metabolic factors are associated with risk of several cancers [36], but
traditional observational studies are not reliable for assessing the association between meta-
bolic factors and cancers strongly associated with smoking. The strength of the association
between BMI and lung cancer subtypes found in this study, were weaker than those reported
in previous MR analyses (45%-81% of risk increase) [18,19]. These previous studies were
based on smaller sample sizes (12,160 and 16,572 lung cancer cases, respectively), whereas our
current study provides causal estimates from 29,266 lung cancer cases and 56,450 controls,
including the samples of previous studies. Our analysis also detected a strong positive effect of
each unit increase in BMI on number of cigarettes smoked per day, indicating that the associa-
tions with risk of squamous and small cell carcinoma lung cancer are caused by an influence of
BMI on smoking behavior. Given that this association was derived from genetic data on BMI,
and therefore not influenced by any inverse effect that tobacco consumption may have on
BMI levels, it has important implications beyond this study on the smoking behavior and
smoking prevention.
Our results lend further support to epidemiological studies showing an increased lung can-
cer risk for the effect of reduced lipid levels [9] and elevated circulating insulin [11]. Several
studies have reported an inverse relationship between total cholesterol levels and cancer
risk [37], which has been previously interpreted as an effect of preclinical cancer due to an
increased uptake of cholesterol by tumor cells [9]. In contrast, our study suggests a potential
relationship between cholesterol levels and lung cancer. However, cholesterol genetic instru-
ments using common and rare SNPs did not provide homogeneous results. This could be
explained by different observations: by the inverse relationship between the instrument set of
common SNPs for cholesterol and BMI revealed by a sensitivity analysis using MR-Base, by a
multiple testing effect, but also by the different proportion of exposure that genetic instru-
ments represent (instrument sets of rare SNPs were weaker and had less power to detect poten-
tial causal associations). Further MR mediation analyses are needed in order to clarify the
causal relationship between lipid levels and lung cancer accounting for the potential effect of
BMI and smoking. Finally, the risk increase observed by fasting glucose and fasting insulin is
unlikely to be driven by cigarette smoking or BMI, since the relevant instrumental sets are not
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associated with smoking or BMI. A potential causal relationship between increased insulin
and cancer risk using genetic instruments has also been reported for endometrial cancer [38]
and pancreatic cancer [39]. These results lend further support for an important role of the
insulin-pathway in cancer aetiology [40–42].
One of the main caveats in Mendelian randomization studies is the potential violation of
methodological assumptions, in particular the lack of directional pleiotropic effects biasing
association estimates. In the current study we evaluated the extent to which pleiotropy may
have affected our risk estimates using MR-Egger regression, as well as the MR-Base platform
to directly assess the relation between genetic instruments and potential confounders.
In conclusion, using a two-sample Mendelian randomization approach, this study assessed
a range of metabolic factors in relation to lung cancer risk. Our results revealed that genetic
associations between BMI and lung cancer subtypes could be mediated by a positive relation-
ship between BMI and cigarette consumption. Our results are also consistent with observa-
tional studies that indicate an inverse relationship between lipid levels and lung cancer risk,
and an increasing risk caused by elevated fasting insulin levels.
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